NO20062130L - 4-(pyrazol-3-ylamino)pyrimidinderivater for anvendelse i behandling av kreft - Google Patents

4-(pyrazol-3-ylamino)pyrimidinderivater for anvendelse i behandling av kreft

Info

Publication number
NO20062130L
NO20062130L NO20062130A NO20062130A NO20062130L NO 20062130 L NO20062130 L NO 20062130L NO 20062130 A NO20062130 A NO 20062130A NO 20062130 A NO20062130 A NO 20062130A NO 20062130 L NO20062130 L NO 20062130L
Authority
NO
Norway
Prior art keywords
ylamino
pyrazol
cancer
treatment
pyrimidine derivatives
Prior art date
Application number
NO20062130A
Other languages
English (en)
Norwegian (no)
Inventor
Thorsten Nowak
Andrew Peter Thomas
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34525049&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20062130(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0324335A external-priority patent/GB0324335D0/en
Priority claimed from GB0412194A external-priority patent/GB0412194D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20062130L publication Critical patent/NO20062130L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20062130A 2003-10-17 2006-05-12 4-(pyrazol-3-ylamino)pyrimidinderivater for anvendelse i behandling av kreft NO20062130L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0324335A GB0324335D0 (en) 2003-10-17 2003-10-17 Novel compounds
GB0412194A GB0412194D0 (en) 2004-06-02 2004-06-02 Novel compounds
PCT/GB2004/004307 WO2005040159A1 (fr) 2003-10-17 2004-10-11 Derives de 4-(pyrazol-3-ylamino) pyrimidine qui s'utilisent dans le traitement du cancer

Publications (1)

Publication Number Publication Date
NO20062130L true NO20062130L (no) 2006-05-12

Family

ID=34525049

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062130A NO20062130L (no) 2003-10-17 2006-05-12 4-(pyrazol-3-ylamino)pyrimidinderivater for anvendelse i behandling av kreft

Country Status (16)

Country Link
US (1) US7579349B2 (fr)
EP (1) EP1678169B1 (fr)
JP (1) JP2007510626A (fr)
KR (1) KR20060123164A (fr)
AR (1) AR046338A1 (fr)
AU (1) AU2004283137A1 (fr)
BR (1) BRPI0415398A (fr)
CA (1) CA2542522A1 (fr)
DE (1) DE602004022187D1 (fr)
ES (1) ES2328820T3 (fr)
IL (1) IL174989A0 (fr)
NO (1) NO20062130L (fr)
SA (1) SA04250338B1 (fr)
TW (1) TW200530229A (fr)
UY (1) UY28565A1 (fr)
WO (1) WO2005040159A1 (fr)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03002294A (es) 2000-09-15 2005-09-08 Vertex Pharma Compuestos de pirazol utiles como inhibidores de proteina cinasa.
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US7601718B2 (en) 2003-02-06 2009-10-13 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
RU2381226C2 (ru) * 2004-02-18 2010-02-10 Астразенека Аб Полигетероциклические соединения и их применение в качестве антагонистов метаботропного рецептора глутамата
WO2006044687A2 (fr) 2004-10-15 2006-04-27 Takeda San Diego, Inc. Inhibiteurs de kinase
JP2008520713A (ja) 2004-11-17 2008-06-19 ミイカナ セラピューティクス インコーポレイテッド キナーゼ阻害剤
ATE519759T1 (de) 2004-12-30 2011-08-15 Exelixis Inc Pyrimidinderivate als kinasemodulatoren und anwendungsverfahren
EP1863797A1 (fr) * 2005-03-23 2007-12-12 AstraZeneca AB 2-azetidinyl-4-(lh-pyrazol-3-ylamino)pyrimidines en tant qu'inhibiteurs de l'activite du recepteur du facteur de croissance insulinique i
MX2007012345A (es) * 2005-04-05 2007-11-23 Astrazeneca Ab Derivados de pirimidina para uso como agentes anticancer.
GB0506886D0 (en) * 2005-04-05 2005-05-11 Astrazeneca Ab Chemical compounds
WO2007023382A2 (fr) * 2005-08-25 2007-03-01 Pfizer Inc. Composes de pyrimidine amino pyrazole, puissants inhibiteurs de kinase
US20090306116A1 (en) * 2005-09-16 2009-12-10 Astrazeneca Ab Pyrimidine derivatives for the inhibition of igf-ir tyrosine kinase activity
ES2535854T3 (es) * 2005-09-30 2015-05-18 Miikana Therapeutics, Inc. Compuestos de pirazol sustituidos
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
RU2427578C2 (ru) 2005-11-03 2011-08-27 Вертекс Фармасьютикалз Инкорпорейтед Аминопиримидины в качестве ингибиторов киназ
CN101360740A (zh) * 2005-11-16 2009-02-04 沃泰克斯药物股份有限公司 可用作激酶抑制剂的氨基嘧啶
WO2007126126A1 (fr) * 2006-04-27 2007-11-08 Banyu Pharmaceutical Co., Ltd. Derive innovant de l'aminopyridine ayant une activite inhibitrice selective d'aurora-a
MX2008016523A (es) * 2006-06-30 2009-01-19 Astrazeneca Ab Derivados de pirimidina utiles en el tratamiento de cancer.
CA2656290A1 (fr) 2006-07-05 2008-01-10 Exelixis, Inc. Procedes d'utilisation de modulateurs de kinase igf1r et abl
GEP20135728B (en) 2006-10-09 2013-01-25 Takeda Pharmaceuticals Co Kinase inhibitors
MX2009004807A (es) 2006-11-02 2009-06-15 Vertex Pharma Aminopiridinas y aminopirimidinas utiles como inhibidores de proteina cinasa.
MX2009006690A (es) * 2006-12-19 2009-07-31 Vertex Pharma Aminopirimidinas utiles como inhibidores de proteinas cinasas.
WO2008112642A1 (fr) 2007-03-09 2008-09-18 Vertex Pharmaceuticals Incorporated Aminopyrimidines utiles en tant qu'inhibiteurs des protéines kinases
RU2009137390A (ru) * 2007-03-09 2011-04-20 Вертекс Фармасьютикалз Инкорпорейтед (Us) Аминопиримидины, пригодные в качестве ингибиторов протеинкиназ
MX2009009592A (es) 2007-03-09 2009-11-10 Vertex Pharma Aminopiridinas utiles como inhibidores de proteinas cinasas.
WO2008117051A1 (fr) * 2007-03-27 2008-10-02 Astrazeneca Ab S-6-méthoxy-2- (2- (3- (pyrimid-2-yl) isoxazol-5-yl) pyrrolidin-1-yl) -4- (5-méthyl-ih-pyrazol-s-ylamino) pyrimidine et ses formes polymorphes utilisées en tant que modulateurs de croissance semblables à l'insuline
NZ580343A (en) 2007-04-13 2012-03-30 Vertex Pharma Aminopyrimidines useful as kinase inhibitors
JP5389786B2 (ja) 2007-05-02 2014-01-15 バーテックス ファーマシューティカルズ インコーポレイテッド キナーゼ阻害として有用なアミノピリミジン
CN101679378A (zh) 2007-05-02 2010-03-24 沃泰克斯药物股份有限公司 用作激酶抑制剂的噻唑和吡唑
JP2010529193A (ja) * 2007-06-11 2010-08-26 ミイカナ セラピューティクス インコーポレイテッド 置換ピラゾール化合物
MX2010001137A (es) * 2007-07-31 2010-03-31 Vertex Pharma Procesopara preparar 5-fluoro-1h-pirazol[3,4-b]piridin-3-amina y derivados del mismo.
WO2009019518A1 (fr) * 2007-08-09 2009-02-12 Astrazeneca Ab Composés de pyrimidine ayant un effet inhibiteur du fgfr
US8278313B2 (en) 2008-03-11 2012-10-02 Abbott Laboratories Macrocyclic spiro pyrimidine derivatives
US8436005B2 (en) 2008-04-03 2013-05-07 Abbott Laboratories Macrocyclic pyrimidine derivatives
AU2010229134A1 (en) * 2009-03-23 2011-11-10 Msd K.K. Novel aminopyridine derivatives having Aurora A selective inhibitory action
EP2411011A4 (fr) * 2009-03-24 2012-08-15 Msd Kk Nouveaux dérivés d'aminopyridine présentant une action inhibitrice sélective de l'aurora a
US20110053916A1 (en) * 2009-08-14 2011-03-03 Vertex Pharmaceuticals Incorporated Pyrimidine compounds as tuberculosis inhibitors
EP2516426B1 (fr) 2009-12-21 2015-09-16 Bayer CropScience AG Bis(difluorométhyl)pyrazoles utilisés comme fongicides
US20120122928A1 (en) 2010-08-11 2012-05-17 Bayer Cropscience Ag Heteroarylpiperidine and -Piperazine Derivatives as Fungicides
EP2423210A1 (fr) 2010-08-25 2012-02-29 Bayer CropScience AG Dérivés d'hétéroarylpipéridine et -pipérazine comme fongicides
US8759527B2 (en) 2010-08-25 2014-06-24 Bayer Cropscience Ag Heteroarylpiperidine and -piperazine derivatives as fungicides
CA2815716C (fr) 2010-10-27 2019-06-11 Bayer Intellectual Property Gmbh Heteroarylpiperidine et derives d'heteroarylpiperidine comme fongicide
CN103492380A (zh) 2011-02-01 2014-01-01 拜耳知识产权有限责任公司 作为杀真菌剂的杂芳基哌啶和杂芳基哌嗪衍生物
EP2532233A1 (fr) 2011-06-07 2012-12-12 Bayer CropScience AG Combinaisons de composés actifs
US10004232B2 (en) 2011-09-15 2018-06-26 Bayer Intellectual Property Gmbh Piperidine pyrazoles as fungicides
DK2921485T3 (en) 2011-12-27 2018-11-12 Bayer Cropscience Ag isoxazole
EP3241830A1 (fr) 2016-05-04 2017-11-08 Bayer CropScience Aktiengesellschaft Derivés de bicycles condensés hétérocycliques utilisés comme pesticides
WO2018193387A1 (fr) 2017-04-19 2018-10-25 Pi Industries Ltd. Composés hétérocycliques ayant des propriétés microbiocides
US20210330672A1 (en) * 2018-07-13 2021-10-28 Teqla Therapeutics Inc. Use of bcl6 inhibitors for treating autoimmune diseases
UY38941A (es) 2019-11-11 2021-06-30 Pi Industries Ltd Nuevas sulfiliminas o sulfoximinas que contienen compuestos heterocíclicos fungicidas
UY38940A (es) 2019-11-11 2021-06-30 Pi Industries Ltd Nuevas piridiniloxi piperidiniletanonas sustituidas
AR120376A1 (es) 2019-11-11 2022-02-09 Pi Industries Ltd Heteroaril piperidiniletanonas sustituidas con actividad fungicida
TW202237143A (zh) 2020-12-10 2022-10-01 南韓商Ｌｇ化學股份有限公司 酸（Ｂｏｒｏｎｉｃ Ａｃｉｄ）化合物
WO2022211595A1 (fr) * 2021-04-01 2022-10-06 주식회사 엘지화학 Composé d'oxadiazole et composition pharmaceutique le comprenant
CN117794527A (zh) * 2021-06-04 2024-03-29 学校法人京都药科大学 新型活化amp的蛋白激酶活化剂
TW202348225A (zh) * 2022-02-25 2023-12-16 美商納羅醫療公司 Myc家族原癌基因蛋白之調節劑
WO2023163712A1 (fr) * 2022-02-25 2023-08-31 Nalo Therapeutics Modulateurs de la protéine proto-oncogène de la famille myc

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2426180A1 (de) * 1974-05-29 1975-12-18 Bayer Ag Verfahren zum faerben von polyurethankunststoffen
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
ATE342892T1 (de) 1998-08-29 2006-11-15 Astrazeneca Ab Pyrimidine verbindungen
US6337338B1 (en) 1998-12-15 2002-01-08 Telik, Inc. Heteroaryl-aryl ureas as IGF-1 receptor antagonists
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
DE19917785A1 (de) 1999-04-20 2000-10-26 Bayer Ag 2,4-Diamino-pyrimidin-Derivate
ATE316781T1 (de) 1999-09-24 2006-02-15 Janssen Pharmaceutica Nv Antivirale feste dispersionen
MXPA02007957A (es) 2000-02-17 2002-11-29 Amgen Inc Inhibidores de cinasas.
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
US7034019B2 (en) 2000-05-08 2006-04-25 Janssen Pharmaceutica N.V. Prodrugs of HIV replication inhibiting pyrimidines
MXPA03002294A (es) 2000-09-15 2005-09-08 Vertex Pharma Compuestos de pirazol utiles como inhibidores de proteina cinasa.
EP1345922B1 (fr) 2000-12-21 2006-05-31 Vertex Pharmaceuticals Incorporated Composes de pyrazole utilises comme inhibiteurs de la proteine kinase
SE0104140D0 (sv) 2001-12-07 2001-12-07 Astrazeneca Ab Novel Compounds

Also Published As

Publication number Publication date
JP2007510626A (ja) 2007-04-26
EP1678169A1 (fr) 2006-07-12
KR20060123164A (ko) 2006-12-01
TW200530229A (en) 2005-09-16
ES2328820T3 (es) 2009-11-18
DE602004022187D1 (de) 2009-09-03
WO2005040159A1 (fr) 2005-05-06
IL174989A0 (en) 2006-08-20
EP1678169B1 (fr) 2009-07-22
SA04250338B1 (ar) 2008-11-18
AU2004283137A1 (en) 2005-05-06
CA2542522A1 (fr) 2005-05-06
UY28565A1 (es) 2005-05-31
BRPI0415398A (pt) 2006-12-19
AR046338A1 (es) 2005-12-07
US20070037888A1 (en) 2007-02-15
US7579349B2 (en) 2009-08-25

Similar Documents

Publication Publication Date Title
NO20062130L (no) 4-(pyrazol-3-ylamino)pyrimidinderivater for anvendelse i behandling av kreft
ATE318267T1 (de) Einige alkylendiamin-substituierte heterocyclen
NO20062763L (no) Pyrrolotriazinforbindelser som kinaseinhibitorer
NO20081003L (no) 2-Aminopyrimidinderivater som modulatorer av histamin-H4-reseptoraktivitet
ATE360627T1 (de) Pyrrolidindion-substituierte piperidin- phthalazone als pde4-inhibitoren
NO20044995L (no) Heterosykliske forbindelser
DK1318992T3 (da) Imidazolderivater som Raf-kinaseinhibitorer
NO20054852L (no) GFAT inhibitorer
MY141521A (en) 5-substituted-six-membered heteroaromatic glucokinase activators
AU2003226572A1 (en) Heteroaryl substituted biphenyl derivatives as p38 kinase inhibitors
MXPA05009063A (es) Compuestos de aminoheteroarilo como inhibidores de proteina cinasa.
ATE324371T1 (de) N-substituierte heterocyclische nichtaryl- nmda/nr2b-antagonisten
ATE477256T1 (de) Thienylverbindungen
NO20062256L (no) Hydroksyalkylsubstituerte pyrido-7-pyrimidin-7-oner
ATE484508T1 (de) Furylverbindungen
NO20064351L (no) Caspaseinhibitorer og anvendelser derav
NO20044526L (no) Hemisterlinderivater og anvendelser derav
TR200201128T2 (tr) PDE4 inhibitörleri olarak tetrahidrotiyopiranfitalazinon türevleri.
IL173809A0 (en) Imidazopyridine derivatives and pharmaceutical compositions containing the same
ATE359283T1 (de) Substituierte pyrazinonverbindungen zur behandlung von entzündungen
NO20074869L (no) Pyrimidinderivater for anvendelse som antikreftmidler
UA80474C2 (en) Aminoheteroaryl compounds as inhibitors of protein kinase
ATE419242T1 (de) Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren
DE60215918D1 (de) Azofarbstoffe
DE60105618D1 (de) Dihydroporphyrinderivate und ihre verwendung

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application